Advaxis confirms long-term stability of its first clinical formulation of ADXS11-001

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has confirmed the long-term stability of its first clinical formulation of ADXS11-001, the Company’s lead immunotherapeutic.

“The ability to make a reproducible live Listeria vaccine with long-term storage stability is an essential part of the commercial development process”

Advaxis has developed and validated novel production methods for the bacterial cancer vaccine currently in clinical trials. The original good manufacturing practice (GMP) batch of the Company’s Listeria-based immunotherapeutic which has been kept in a frozen state has been tested and found to be stable and to still meet release specifications approximately four years and nine months after manufacture.

“The ability to make a reproducible live Listeria vaccine with long-term storage stability is an essential part of the commercial development process,” commented Advaxis Chairman/CEO Thomas A. Moore. “As we continue to refine our FDA-approved production methods, further research may produce substantive improvements.”